New developments in imaging and functional biomarker technology for the assessment and management of cancer patients

References

• Yang DJ, Kim EE, Inoue T. Targeted molecular imaging in oncology. Ann. Nucl. Med.20(1), 1–11 (2006).
   PubMed Web of Science ®Google Scholar
• Weissleder R. Molecular imaging in cancer. Science312(5777), 1168–1171 (2006).
   PubMed Web of Science ®Google Scholar
• Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature452(7187), 580–589 (2008).
   PubMed Web of Science ®Google Scholar
• Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu. Rev. Med.57, 99–118 (2006).
   PubMed Web of Science ®Google Scholar
• Wester HJ. Nuclear imaging probes: from bench to bedside. Clin. Cancer Res.13(12), 3470–3481 (2007).
   Google Scholar
• Glunde K, Pathak AP, Bhujwalla ZM. Molecular-functional imaging of cancer: to image and imagine. Trends Mol. Med.13(7), 287–297 (2007).
   PubMed Web of Science ®Google Scholar
• Weber WA, Czernin J, Phelps ME, Herschman HR. Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat. Clin. Pract. Oncol.5(1), 44–54 (2008).
   Google Scholar
• Serganova I, Blasberg RG. Multi-modality molecular imaging of tumors. Hematol. Oncol. Clin. North Am.20(6), 1215–1248 (2006).
   Google Scholar
• Papathanassiou D, Liehn JC. The growing development of multimodality imaging in oncology. Crit. Rev. Oncol. Hematol.68(1), 60–65 (2008).
   PubMed Web of Science ®Google Scholar
• Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat. Rev. Drug Discov.7(7), 591–607 (2008).
   PubMed Web of Science ®Google Scholar
• Pomper MG. Translational molecular imaging for cancer. Cancer Imaging5(Spec. No. A), S16–S26 (2005).
   Google Scholar
• Niu G, Chen X. Has molecular and cellular imaging enhanced drug discovery and drug development?. Drugs R. D.9(6), 351–368 (2008).
   Google Scholar
• Mather S. Molecular imaging with bioconjugates in mouse models of cancer. Bioconjug. Chem.20(4), 631–643 (2009).
   PubMedGoogle Scholar
• Koo V, Hamilton PW, Williamson K. Non-invasive in vivo imaging in small animal research. Cell. Oncol.28(4), 127–139 (2006).
   PubMedGoogle Scholar
• Lyons SK. Advances in imaging mouse tumour models in vivo. J. Pathol.205(2), 194–205 (2005).
   PubMed Web of Science ®Google Scholar
• Mankoff DA. Molecular imaging as a tool for translating breast cancer science. Breast Cancer Res.10(Suppl. 1), S3 (2008).
   PubMedGoogle Scholar
• Imam SK. Molecular nuclear imaging: the radiopharmaceuticals (review). Cancer Biother. Radiopharm.20(2), 163–172 (2005).
   PubMed Web of Science ®Google Scholar
• Hoffman JM, Gambhir SS, Kelloff GJ. Regulatory and reimbursement challenges for molecular imaging. Radiology245(3), 645–660 (2007).
   Google Scholar
• Coleman RE. Single photon emission computed tomography and positron emission tomography in cancer imaging. Cancer67(4 Suppl.), 1261–1270 (1991).
   Google Scholar
• Maldonado A, González-Alenda FJ, Alonso M, Sierra JM. PET-CT in clinical oncology. Clin. Transl. Oncol.9(8), 494–505 (2007).
   Google Scholar
• Townsend DW. Positron emission tomography/computed tomography. Semin. Nucl. Med.38(3), 152–166 (2008).
   Google Scholar
• Chowdhury FU, Scarsbrook AF. The role of hybrid SPECT-CT in oncology: current and emerging clinical applications. Clin. Radiol.63(3), 241–251 (2008).
   PubMedGoogle Scholar
• Tagliabue L, Schillaci O. SPECT/CT in oncology: the fusion of two imaging modalities is a new standard of care. Q. J. Nucl. Med. Mol. Imaging51(4), 285–289 (2007).
   Google Scholar
• Maurer AH. Combined imaging modalities: PET/CT and SPECT/CT. Health Phys.95(5), 571–576 (2008).
   Google Scholar
• Hicks RJ, Lau EW. PET/MRI: a different spin from under the rim. Eur. J. Nucl. Med. Mol. Imaging36(Suppl. 1), S10–S14 (2009).
   Google Scholar
• Morikawa M, Demura Y, Ishizaki T et al. The effectiveness of 18F-FDG PET/CT combined with STIR MRI for diagnosing nodal involvement in the thorax. J. Nucl. Med.50(1), 81–87 (2009).
   Google Scholar
• Seiboth L, Van Nostrand D, Wartofsky L et al. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. Thyroid18(2), 103–111 (2008).
   Google Scholar
• Moy L, Ponzo F, Noz ME et al. Improving specificity of breast MRI using prone PET and fused MRI and PET 3D volume datasets. J. Nucl. Med.48(4), 528–537 (2007).
   Google Scholar
• Ruf J, Lopez Hanninen E, Bohmig M et al. Impact of FDG-PET/MRI image fusion on the detection of pancreatic cancer. Pancreatology6(6), 512–519 (2006).
   PubMed Web of Science ®Google Scholar
• Pichler BJ, Judenhofer MS, Wehrl HF. PET/MRI hybrid imaging: devices and initial results. Eur. Radiol.18(6), 1077–1086 (2008).
   PubMed Web of Science ®Google Scholar
• Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging?. Eur. J. Nucl. Med. Mol. Imaging36(Suppl. 1), S113–S120 (2009).
   Web of Science ®Google Scholar
• Tang Z, Du R, Jiang S et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br. J. Cancer99(6), 911–922 (2008).
   PubMed Web of Science ®Google Scholar
• Judenhofer MS, Wehrl HF, Newport DF et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat. Med.14(4), 459–465 (2008).
   PubMed Web of Science ®Google Scholar
• Choyke PL, Knopp MV, Libutti SK. Special techniques for imaging blood flow to tumors. Cancer J.8(2), 109–118 (2002).
   Google Scholar
• Knopp MV, von Tengg-Kobligk H, Choyke PL. Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring. Mol. Cancer Ther.2(4), 419–426 (2003).
   PubMed Web of Science ®Google Scholar
• Nanni C, Rubello D, Khan S, Al-Nahhas A, Fanti S. Role of small animal PET in stimulating the development of new radiopharmaceuticals in oncology. Nucl. Med. Commun.28(6), 427–429 (2007).
   Google Scholar
• Franc BL, Acton PD, Mari C, Hasegawa BH. Small-animal SPECT and SPECT/CT: important tools for preclinical investigation. J. Nucl. Med.49(10), 1651–1663 (2008).
   PubMed Web of Science ®Google Scholar
• Wang J, Maurer L. Positron emission tomography: applications in drug discovery and drug development. Curr. Top. Med. Chem.5(11), 1053–1075 (2005).
   PubMed Web of Science ®Google Scholar
• Acton PD, Kung HF. Small animal imaging with high resolution single photon emission tomography. Nucl. Med. Biol.30(8), 889–895 (2003).
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst.92(3), 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur. J. Cancer42(8), 1031–1039 (2006).
   PubMed Web of Science ®Google Scholar
• Hillman BJ, Gatsonis C. The American College of Radiology Imaging Network – clinical trials of diagnostic imaging and image-guided treatment. Semin. Oncol.35(5), 460–469 (2008).
   Google Scholar
• Sikora K. Personalized medicine for cancer: from molecular signature to therapeutic choice. Adv. Cancer Res.96, 345–369 (2007).
   Google Scholar
• Hoffman JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology244(1), 39–47 (2007).
   PubMed Web of Science ®Google Scholar
• Lawrence YR, Werner-Wasik M, Dicker AP. Biologically conformal treatment: biomarkers and functional imaging in radiation oncology. Future Oncol.4(5), 689–704 (2008).
   Google Scholar
• Hall NC, Povoski SP, Murrey DA, Knopp MV, Martin EW. Bringing advanced medical imaging into the operative arena could revolutionize the surgical care of cancer patients. Expert Rev. Med. Devices5(6), 663–667 (2008).
   PubMed Web of Science ®Google Scholar